Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone + granisetron is a combination of two pharmaceutical agents used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties. Granisetron is a selective serotonin (5-HT3) receptor antagonist that blocks serotonin-mediated signaling in both the central nervous system (chemoreceptor trigger zone) and peripheral nervous system (gastrointestinal tract), thereby inhibiting the emetic reflex. The combination has been shown to be more effective than either agent alone in preventing both acute and delayed emesis induced by highly or moderately emetogenic chemotherapy regimens, as well as postoperative nausea and vomiting[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + granisetron.